Login to Your Account

Clinic roundup

Tuesday, May 13, 2014
Amgen Inc., of Thousand Oaks, Calif., and Astrazeneca plc, of London, reported that the phase III AMAGINE-1 study testing brodalumab, a drug designed to bind to the interleukin-17 receptor, in patients with moderate to severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription